Skip to Content

Viberzi (eluxadoline) Disease Interactions

There are 3 disease interactions with Viberzi (eluxadoline):

Major

Eluxadoline (Includes Viberzi) ↔ Constipation

Severe Potential Hazard, Moderate plausibility

Applies to: Constipation, Gastrointestinal Obstruction

The use of eluxadoline is contraindicated in patients with history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction. These patients may be at risk for severe complications of bowel obstruction.

Major

Eluxadoline (Includes Viberzi) ↔ Pancreatitis

Severe Potential Hazard, Moderate plausibility

Applies to: Pancreatitis, Biliary Obstruction, Gallbladder Disease, Alcoholism

Pancreatitis, with or without sphincter of Oddi spasm has been reported in patients taking either the 75 mg or 100 mg dosage of eluxadoline, including serious cases resulting in hospitalization, primarily in patients without a gallbladder. Fatal cases have also been reported. The use of eluxadoline is contraindicated in patients without a gallbladder and in other patients at risk of pancreatitis such as patients with alcoholism, patients with known or suspected bile duct obstruction, history of pancreatitis or structural disease of the pancreas. In patients with a gallbladder, the alcohol intake of the patient should be evaluated before starting treatment. Patients should be monitored for any signs or symptoms suggestive of pancreatitis. Patients should be instructed to stop treatment immediately and seek medical attention.

Major

Eluxadoline (Includes Viberzi) ↔ Hepatic Impairment

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Eluxadoline is contraindicated in patients with severe hepatic impairment, as these patients are at risk for significantly increased plasma concentrations (16- fold), and there is no information to support the safety on these patients. In patients with mild to moderate hepatic impairment the plasma concentrations are increased to a lesser extent. It is recommended to decrease the dose to 75 mg twice a day on these patients and monitor regularly for impaired mental or physical abilities and for any other eluxadoline related adverse reactions.

Viberzi (eluxadoline) drug Interactions

There are 558 drug interactions with Viberzi (eluxadoline)

Viberzi (eluxadoline) alcohol/food Interactions

There is 1 alcohol/food interaction with Viberzi (eluxadoline)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide